Home > Publications database > Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. > print

001     128816
005     20240228143350.0
024 7 _ |a 10.3324/haematol.2015.141622
|2 doi
024 7 _ |a pmid:27036160
|2 pmid
024 7 _ |a pmc:PMC5004463
|2 pmc
024 7 _ |a 0390-6078
|2 ISSN
024 7 _ |a 1592-8721
|2 ISSN
024 7 _ |a altmetric:6428717
|2 altmetric
037 _ _ |a DKFZ-2017-04829
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Hütter-Krönke, Marie-Luise
|b 0
245 _ _ |a Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
260 _ _ |a Pavia
|c 2016
|b Ferrata Storti Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522056644_26909
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51%) and partial remission in 10 (11%) patients resulting in an overall response rate of 61.5%; 33 (35.5%) patients had refractory disease and 3 patients (3%) died. Allogeneic hematopoietic cell transplantation was performed in 71 (76%) patients; 6 of the 71 (8.5%) patients developed moderate or severe sinusoidal obstruction syndrome after transplantation. Four-year overall survival rate was 32% (95% confidence interval 24%-43%). Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation (n=51) had a 4-year survival rate of 49% (95% confidence intervaI 37%-64%). Patients with fms-like tyrosine kinase internal tandem duplication positive acute myeloid leukemia had a poor outcome despite transplantation. In conclusion, the described regimen is an effective and tolerable salvage therapy for patients who are primary refractory to one cycle of conventional intensive induction therapy. (clinicaltrials.gov identifier: 00143975).
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Aminoglycosides
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Cytarabine
|0 04079A1RDZ
|2 NLM Chemicals
650 _ 7 |a Tretinoin
|0 5688UTC01R
|2 NLM Chemicals
650 _ 7 |a gemtuzumab
|0 93NS566KF7
|2 NLM Chemicals
650 _ 7 |a Mitoxantrone
|0 BZ114NVM5P
|2 NLM Chemicals
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 1
|u dkfz
700 1 _ |a Döhner, Konstanze
|b 2
700 1 _ |a Krauter, Jürgen
|b 3
700 1 _ |a Weber, Daniela
|b 4
700 1 _ |a Moessner, Margit
|b 5
700 1 _ |a Köhne, Claus-Henning
|b 6
700 1 _ |a Horst, Heinz A
|b 7
700 1 _ |a Schmidt-Wolf, Ingo G H
|b 8
700 1 _ |a Rummel, Mathias
|b 9
700 1 _ |a Götze, Katharina
|b 10
700 1 _ |a Koller, Elisabeth
|b 11
700 1 _ |a Petzer, Andreas L
|b 12
700 1 _ |a Salwender, Hans
|b 13
700 1 _ |a Fiedler, Walter
|b 14
700 1 _ |a Kirchen, Heinz
|b 15
700 1 _ |a Haase, Detlef
|b 16
700 1 _ |a Kremers, Stephan
|b 17
700 1 _ |a Theobald, Matthias
|b 18
700 1 _ |a Matzdorff, Axel C
|b 19
700 1 _ |a Ganser, Arnold
|b 20
700 1 _ |a Döhner, Hartmut
|b 21
700 1 _ |a Schlenk, Richard F
|b 22
773 _ _ |a 10.3324/haematol.2015.141622
|g Vol. 101, no. 7, p. 839 - 845
|0 PERI:(DE-600)2805244-4
|n 7
|p 839 - 845
|t Haematologica
|v 101
|y 2016
|x 1592-8721
909 C O |o oai:inrepo02.dkfz.de:128816
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21